Clinical Trial Update: FR901228 in Treating Patients With Relapsed or Refractory Advanced Ovarian Epithelial Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial of FR901228 for relapsed or refractory advanced ovarian epithelial cancer has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ovarian Cancer

Drugs mentioned

• FR901228 (romidepsin)

Snippet

Sponsor: University of Chicago | Conditions: Ovarian Cancer | Phase 2 | Status: WITHDRAWN